Optimal Strategies in the Management of CMV in Solid Organ Transplantation

The transplantation of solid organs is one of the most complex medical endeavors and a common lifesaving therapy for those with end-stage renal disease (ESRD), liver failure, heart disease, lung, and pancreatic failure. Among patients undergoing solid organ transplantation, CMV is the single most important pathogen that affects the outcome of the procedure as detected by plasma igG outcomes, prevention of CMV infection is a key component of solid organ transplant care.

Two strategies are used to prevent CMV infection: antiviral prophylaxis and preemptive treatment. Each of these strategies has inherent advantages and limitations and there is widespread controversy as to the best method for prevention of CMV in solid organ transplant patients. In addition, there are challenges associated with the diagnosis of CMV as well as the ideal prevention strategy and therapeutic agent.

Available until December 31, 2010, this activity offers:
Physicians: 1.0 AMA PRA Category 1 Credit^™
Nurses: 1.0 contact hours

This activity is jointly sponsored by:

This activity is supported by an educational grant from Roche.
 

 

[Back to top]

[Back to Activity Home]